These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Circulating mircoRNA-21 as a predictor for vascular restenosis after interventional therapy in patients with lower extremity arterial occlusive disease. Zhang B, Yao Y, Sun QF, Liu SQ, Jing B, Yuan C, Liu XY, Jiao T, Li HC, Wang HY. Biosci Rep; 2017 Apr 30; 37(2):. PubMed ID: 28250135 [Abstract] [Full Text] [Related]
7. Potential of circulating pro-angiogenic microRNA expressions as biomarkers for rapid angiographic stenotic progression and restenosis risks in coronary artery disease patients underwent percutaneous coronary intervention. Dai R, Liu Y, Zhou Y, Xiong X, Zhou W, Li W, Zhou W, Chen M. J Clin Lab Anal; 2020 Jan 30; 34(1):e23013. PubMed ID: 31495986 [Abstract] [Full Text] [Related]
9. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting. Zhao K, Li YJ, Gao S. Coron Artery Dis; 2015 May 30; 26(3):220-4. PubMed ID: 25647458 [Abstract] [Full Text] [Related]
12. The association of red cell distribution width with in-stent restenosis in patients with stable coronary artery disease. Kurtul A, Murat SN, Yarlioglues M, Duran M, Karadeniz M, Ergun G, Akyel A, Mendi MA, Oksuz F. Platelets; 2015 May 30; 26(1):48-52. PubMed ID: 24831828 [Abstract] [Full Text] [Related]
13. MiR-140-3p is Involved in In-Stent Restenosis by Targeting C-Myb and BCL-2 in Peripheral Artery Disease. Zhu ZR, He Q, Wu WB, Chang GQ, Yao C, Zhao Y, Wang M, Wang SM. J Atheroscler Thromb; 2018 Nov 01; 25(11):1168-1181. PubMed ID: 29760303 [Abstract] [Full Text] [Related]
14. [Effects of miRNA-1,miRNA-21 in plasma on in-stent restenosis in patients with coronary heart disease and diabetes mellitus after percutaneous coronary intervention]. Guan JJ, Zhang Y, Liu YJ. Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2018 Apr 08; 34(4):304-308 384. PubMed ID: 30788936 [Abstract] [Full Text] [Related]
15. Circulating microRNA-21 as Stable Blood-Based Markers for Patients With ISR After PCI. Zhang X, Xiao XP, Ren XA, Xue W. Heart Surg Forum; 2020 Oct 14; 23(6):E756-E762. PubMed ID: 33234202 [Abstract] [Full Text] [Related]
16. Increased plasma olfactomedin 2 after interventional therapy is a predictor for restenosis in lower extremity arteriosclerosis obliterans patients. Li H, Gui H, Yuan G, Zheng X, Gao C, Yuan H. Scand J Clin Lab Invest; 2018 Jul 14; 78(4):269-274. PubMed ID: 29553861 [Abstract] [Full Text] [Related]
17. Rationale and study design of the CardioGene Study: genomics of in-stent restenosis. Ganesh SK, Skelding KA, Mehta L, O'Neill K, Joo J, Zheng G, Goldstein J, Simari R, Billings E, Geller NL, Holmes D, O'Neill WW, Nabel EG. Pharmacogenomics; 2004 Oct 14; 5(7):952-1004. PubMed ID: 15469413 [Abstract] [Full Text] [Related]
18. The Diagnostic Value of Circulating Biomarkers and Role of Drug-Coated Balloons for In-Stent Restenosis in Patients with Peripheral Arterial Disease. Montelione N, Catanese V, Nenna A, Jawabra M, Verghi E, Loreni F, Nappi F, Lusini M, Mastroianni C, Jiritano F, Serraino GF, Mastroroberto P, Codispoti FA, Chello M, Spinelli F, Stilo F. Diagnostics (Basel); 2022 Sep 12; 12(9):. PubMed ID: 36140608 [Abstract] [Full Text] [Related]